6-K ·Filed Jul 9, 2026

TAK

TAKEDA PHARMACEUTICAL CO LTD
NEUTRAL
Impact 2/10
Horizonimmediate Processed2mo ago SEC0001395064-26-000280
Notable filing: 6-K
Actionable Insight • Neutral

Routine governance filing with no new financial data or corporate events. Monitor next quarterly earnings for revenue and earnings trends.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+20d ⚠ clustered
TAK ▲ +2.47% at T+20d
NEUTRAL call ✓ call won +2.47% · α vs SPY +0.23% · entry $16.61 → $17.02
Next anchor: T+60d due 9h ago
Latest observation: T+57 +16.63% FF3 residual α
Entry anchored
Jul 8, 03:59 PM ET
via exchange tick
T+1d
-0.30%
call -0.30% · α -0.73%
$16.56
settled 3mo ago
T+5d
+0.72%
call +0.72% · α +0.85%
$16.73
settled 3mo ago
T+20d
+2.47%
call +2.47% · α +0.23%
$17.02
settled 8w ago
T+60d
—
call — · α —
—
due 9h ago

Price Chart

Loading chart...

Executive Summary

Takeda filed its annual Corporate Governance Report, confirming compliance with all principles of the Corporate Governance Code. The report details board composition (8 of 11 directors are independent external directors, chair is independent), board effectiveness evaluation, and director compensation policy. No material financial or operational updates were disclosed.

Key Facts

  • Company in full compliance with all Corporate Governance Code principles
  • Board comprises 11 directors; 8 are independent external directors (majority); board chair is an independent external director
  • No anti-takeover measures adopted; no parent company or major shareholder above 10%
  • Board effectiveness evaluation concluded the BOD is operating effectively, noting a transition period with CEO succession and director offboarding
  • Director compensation includes performance-based bonuses and long-term incentives (PSUs/RSUs) with clawback policy

Financial Impact

No financial figures reported

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
68% bullish (19 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001395064-26-000280
Document: form6k_070926.htm0001395064-26-000280
Document: 0001395064-26-000280-index-headers.html0001395064-26-000280
Document: 0001395064-26-000280-index.html0001395064-26-000280
Document: 0001395064-26-000280.txt0001395064-26-000280
13 reports for TAK
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for TAK — sortable, filterable
TypeNow
Sep 14, 2026
18d ago
6-K
BULLISH ★ 7/10
$18.60 $18.89▲ +1.56%▲ +1.45%$17.86 (−3.98%)
Aug 21, 2026
6w ago
Insider Cluster
NEUTRAL ★ 2/10
$18.18 $18.03▼ −0.83%▼ −1.30%$17.86 (−1.76%)
Aug 19, 2026
6w ago
Insider Cluster
NEUTRAL ★ 2/10
$18.34 $18.23▼ −0.60%▼ −0.21%$17.86 (−2.62%)
Aug 14, 2026
7w ago
Court Ruling
NEUTRAL ★ 4/10
$17.63 $18.18▲ +3.12%▲ +4.49%$17.86 (+1.30%)
Aug 13, 2026
7w ago
Insider Cluster
NEUTRAL ★ 3/10
$17.39 $18.13▲ +4.26%▲ +6.22%$17.86 (+2.70%)
Aug 13, 2026
7w ago
Insider Cluster
NEUTRAL ★ 2/10
$17.39 $18.13▲ +4.26%▲ +6.22%$17.86 (+2.70%)
Jul 9, 2026
12w ago
6-K
NEUTRAL ★ 2/10
$16.61 $16.73▲ +0.72%▲ +0.85%$17.86 (+7.53%)
Jul 8, 2026
12w ago
6-K
NEUTRAL ★ 2/10
$16.75 $16.39▼ −2.15%▼ −3.01%$17.86 (+6.63%)
Jul 6, 2026
12w ago
3
NEUTRAL ★ 2/10
$16.89 $16.56▼ −1.95%▼ −2.44%$17.86 (+5.74%)
Jun 29, 2026
13w ago
6-K
NEUTRAL ★ 2/10
$15.98 $16.89▲ +5.69%▲ +4.31%$17.86 (+11.76%)
Showing 10 of 13

US Market Status

Market Closed — Opens Mon (64h 59m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access